SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alfacell (ACEL)
ACEL 11.28+1.0%Feb 6 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Greg Kevorkian who wrote (550)7/1/1997 12:28:00 AM
From: Gil Kempenich   of 1533
 
I recently spoke to an Oncologist friend who works in Toronto in Canada's foremost cancer center. He has heard of Onconase but has never used it. His opinion of Gemzar is very low. His assessment is that it slightly improves the quality of life, for a short period at best, but has little value therapeutically. He views Gemzar's success a result of 1) the fact that there is nothing else for treatment of pancreatic cancer and 2) that the company has done an excellent job of marketing the drug. He feels that Alfacell cannot adequately market Onconase itself. It requires a massive effort, a trained, extensive marketing staff, and in-depth marketing expertise. He does not believe that Alfacell would market Onconase itself. While he of course has not concrete knowledge of what is truly on their minds, he suspects that the company might hope to be bought out by one of the majors.

All this is of course speculation, but it is an interesting and intriguing prospect. Any thoughts?

Gil
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News